Degranin Therapeutics
Biopharmaceutical company developing a first-in-class therapeutic candidate that targets neutrophil degranulation to treat Acute Respiratory Distress Syndrome (ARDS). The team combines clinical medicine and laboratory research experience from an academic medical center and is advancing a lead candidate through preclinical development with Phase II SBIR funding and manufacturing scale-up efforts.
Industries
N/A
Nr. of Employees
small (1-50)
Products
DGN 44 (lead therapeutic candidate)
A first-in-class therapeutic candidate that inhibits neutrophil degranulation to reduce lung injury and inflammation in ARDS.
DGN 44 (lead therapeutic candidate)
A first-in-class therapeutic candidate that inhibits neutrophil degranulation to reduce lung injury and inflammation in ARDS.
Services
Engagements for investment, strategic partnerships, scientific collaboration, and licensing related to ARDS therapeutics.
Engagements for investment, strategic partnerships, scientific collaboration, and licensing related to ARDS therapeutics.
Expertise Areas
- ARDS therapeutics development
- Neutrophil biology
- Preclinical efficacy testing
- Recombinant protein expression and characterization
Key Technologies
- Neutrophil degranulation inhibition
- Recombinant protein expression
- Preclinical viral ARDS models
- Immunophenotyping
News & Updates
Received Phase II Small Business Innovation Research (SBIR) funding to support development of the lead therapeutic candidate.
Received Phase II Small Business Innovation Research (SBIR) funding to support development of the lead therapeutic candidate.